Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.

MLA

Chalker, Cameron, et al. “Performance Status (PS) as a Predictor of Poor Response to Immune Checkpoint Inhibitors (ICI) in Recurrent/Metastatic Head and Neck Cancer (RMHNSCC) Patients.” Cancer Medicine, vol. 11, no. 22, Nov. 2022, pp. 4104–11. EBSCOhost, https://doi.org/10.1002/cam4.4722.

APA

Chalker, C., Voutsinas, J. M., Wu, Q. V., Santana-Davila, R., Hwang, V., Baik, C. S., Lee, S., Barber, B., Futran, N. D., Houlton, J. J., Laramore, G. E., Liao, J. J., Parvathaneni, U., Martins, R. G., Eaton, K. D., & Rodriguez, C. P. (2022). Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients. Cancer Medicine, 11(22), 4104–4111. https://doi.org/10.1002/cam4.4722

Chicago

Chalker, Cameron, Jenna M Voutsinas, Qian Vicky Wu, Rafael Santana-Davila, Victoria Hwang, Christina S Baik, Sylvia Lee, et al. 2022. “Performance Status (PS) as a Predictor of Poor Response to Immune Checkpoint Inhibitors (ICI) in Recurrent/Metastatic Head and Neck Cancer (RMHNSCC) Patients.” Cancer Medicine 11 (22): 4104–11. doi:10.1002/cam4.4722.